Eddy Anglade, Tenpoint Therapeutics CEO

Ten­point Ther­a­peu­tics launch­es with $70M to re­store vi­sion with stem cell ther­a­pies and ‘re­pro­gram­ming’ med­i­cines

Al­though nu­mer­ous biotech com­pa­nies are de­vel­op­ing gene ther­a­pies to cor­rect eye­sight, these ap­proach­es large­ly re­quire the af­fect­ed cells to re­main in­tact — while many forms of vi­sion loss are caused by dead or dy­ing cells. That’s why a new start­up is bet­ting that ad­vances in stem cell bi­ol­o­gy will en­able treat­ments that re­store vi­sion by re­plac­ing or re­gen­er­at­ing vi­tal tis­sues lost to dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA